Artelo Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

EQUITY (Detail Narrative)

EQUITY (Detail Narrative)						1 Months Ended			12 Months Ended
EQUITY (Detail Narrative)	Mar. 05, 2021 $ / shares shares	Feb. 12, 2021 $ / shares shares	Oct. 14, 2020 shares	Oct. 09, 2020 shares	Mar. 15, 2019 USD ($) shares	Jul. 21, 2021 $ / shares shares	Nov. 30, 2020 $ / shares shares	Jun. 25, 2019 USD ($) integer $ / shares shares	Aug. 31, 2021 USD ($) $ / shares shares	Aug. 31, 2020 USD ($) $ / shares shares	Aug. 31, 2019 USD ($) $ / shares	Dec. 03, 2020 $ / shares shares	Oct. 10, 2020 shares	Sep. 01, 2020 shares	Jun. 20, 2019 shares
Common stock, par value (in dollars per share) \| $ / shares								$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized									750,000,000	750,000,000		18,750,000,000			150,000,000,000
Preferred stock, par value (in dollars per share) \| $ / shares									$ 0.001	$ 0.001
Preferred stock, shares authorized									6,250,000	6,250,000					50,000,000,000
Preferred stock, shares outstanding									0	0
Preferred stock, shares issued									0	0
Common shares issued for cash \| $									$ 8,103,000	$ 1,978,000	$ 8,376,379,000
Common shares issued for settlement of debt \| $										$ 100,000
Exercise price of warrants \| $ / shares								$ 6.4575
Number of warrant purchase \| integer								1
Number of purchase common stock shares \| integer								1
Number of units sold								1,300,813,000
Number of warrant granted									10,120,000,000	0
Common stock, shares issued									24,526,703	4,991,587
Proceeds from warrant exercises \| $									$ 6,016,000	$ 0
Director [Member]
Number of cancelled common shares										6,250,000
Amount of refund common shares \| $										$ 2,500,000
Over-Allotment Option [Member]
Exercise price of warrants \| $ / shares								$ 6.765
Number of warrant purchase \| integer								104,065
Number of units sold								191,102,000
Share price \| $ / shares								$ 0.01
Terms of common stock warrant								3 years
Offering price, per unit \| $ / shares								$ 6.15
Number of additional shares purchased								195,121,000
Gross proceeds before deducting underwriting discounts and commissions \| $								$ 8,001,911,000
Percentage Of Underwriting Discounts And Commissions								0.08%
Proceeds from warrant exercises \| $								$ 1,911,000
Blackrock Ventures Ltd [Member]
Common shares issued for cash \| $					$ 240,000,000
Common shares issued for cash (in shares)					25,000,000
Represents information of officer and director.
Common shares issued for cash \| $										$ 55,000,000
Common shares issued for cash (in shares)										45,834,000
Common Stock [Member]
Common stock, par value (in dollars per share) \| $ / shares									$ 0.001
Common shares issued for cash \| $										$ 1,978,000
Common shares issued for settlement of debt \| $										11,000
Common stock, shares issued									19,535,116
Expenses payable \| $									$ 6,579
Common stock , shares issued for exercise of warrants									8,021,525
Proceeds from exercise of warrants \| $									$ 6,016
Offering costs \| $									$ 96	$ 1,923
Common stock, shares issued during period									1,393,591
Net proceeds \| $									$ 1,524
Average price \| $ / shares									$ 1.20
Commission fee \| $									$ 51
Additional common shares issued (shares)										7,373,000
Number of issuance of common shares										1,644,221,000
Common shares issued for cash (in shares)									17,774,310,000	1,564,188,000
Common shares issued for acquisition of license (in shares)										61,297,000
Common shares issued for settlement of debt (in shares)										11,363,000
Reverse stock split adjustment (shares)										10,000
Represents information about Series D Common Stock Purchase Warrant.
Exercise price of warrants \| $ / shares									$ 14.00
Share price \| $ / shares									6.00
Represents as a common Series E purchase warrant.
Exercise price of warrants \| $ / shares									16.00
Share price \| $ / shares									$ 7.60
Represents as a common class A and B purchase warrant.
Exercise price of warrants \| $ / shares										$ 16.00
Represents as a common class A and B purchase warrant. \| Stock purchase agreement.
Warrant intrinsic value \| $										$ 0
Represents as a common class A and B purchase warrant. \| Stock purchase agreement. \| Minimum [Member]
Exercise price of warrants \| $ / shares										$ 8.00
Represents as a common class A and B purchase warrant. \| Stock purchase agreement. \| Maximum [Member]
Exercise price of warrants \| $ / shares										$ 14.00
Valuation [Member]
Options Granted									2,755,100	74,000
Option Granted, Value \| $									$ 5,760	$ 190
Stock option expense \| $									1,497	336
Stock option expense, Related parties \| $									1,340	289
Stock option expense, Unamortized \| $									4,263	409
Stock option expense, Unamortized, Related parties \| $									$ 3,664	$ 318
Options Outstanding									2,859,184	281,834
Options Outstanding, intrinsic value \| $									$ 37	$ 0
Options granted in fiscal year 2021 [Member]
Exercise price \| $ / shares	$ 1.52	$ 2.66				$ 1.00	$ 0.6035
Options granted to purchase shares of common stock	575,100	834,500				70,000
Options Granted							120,000
Options grant description							The Company anticipates the compensation to be $15 to $20 per year for the first year and $20 to $30 for the second year and thereafter, subject to formal approval by the Board.
Options granted in fiscal year 2021 [Member] \| Options 1 [Member]
Exercise price \| $ / shares	$ 1.52	$ 2.66
Options granted to purchase shares of common stock	30,000	705,500
Options granted in fiscal year 2021 [Member] \| Options 2 [Member]
Exercise price \| $ / shares		$ 2.66
Options granted to purchase shares of common stock		420,000
Options forfeited in fiscal year 2021 [Member]
Unvested stock options						177,750
Vested stock options						23,750
Represents as a equity incentive plan. \| January 1, 2020
Common shares issued for cash \| $										$ 1,922,691,000
Common shares issued for cash (in shares)										1,518,354,000
Percentage of compensation commission rate per share of common stock										0.20%
Underwriting Agreement [Member] \| Over-Allotment Option [Member] \| Ladenburg Thalmann [Member]
Number of units sold			1,320,000,000
Common shares issued for cash (in shares)				1,320,000,000
Number of warrants sold			1,320,000,000										1,320,000,000
2018 Equity Incentive Plan
Common stock reserved for future issuance									2,000,000					1,548,738,000
Common stock, shares issuable									3,548,738
Common stock, shares available to be issued									689,554